Free Trial
NASDAQ:CVAC

CureVac Q1 2023 Earnings Report

CureVac logo
$4.77 +0.33 (+7.52%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.29
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$7.65 million
Expected Revenue
$16.45 million
Beat/Miss
Missed by -$8.80 million
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Tuesday, May 30, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

CureVac's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

CureVac Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
CureVac FY2025 EPS Forecast Increased by Leerink Partnrs
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat